Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DOR BioPharma, (DORB) -- Ignore unavailable to you. Want to Upgrade?

To: Paul Lee who wrote (18)	11/25/2008 1:45:36 PM
From: Findit	Read Replies (1) \| Respond to of 35

DORB .09 +20%. They are bidding their time waiting on the FDA to be cooperative. They know this will continue to take forever. So in the meantime they are opening avenues around the world for their drug orBec. Good strategy. This will be a big winner one day. I will continue to hold a bunch for the real win and trade some along the way. May take another year or two, but can be a worthwhile venture for the patient. Jim DOR BioPharma's orBec(R) Receives Orphan Drug Designation in Australia for the Treatment of GI GVHD 8:13 AM EST November 25, 2008